Drug Trial Radar · NCT05727904
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
670
Planned (sponsor's estimate)
Start
Mar 30, 2023
Primary completion
Mar 1, 2028
Study completion Mar 1, 2030
Sponsor
- Lead sponsor
- Iovance Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.
Conditions
- Metastatic Melanoma
- Unresectable Melanoma
- Melanoma
Interventions
Lifileucel plus PembrolizumabBiological
A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive Pembrolizumab followed by the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2. Patients will then continue to receive Pembrolizumab every 6 weeks until disease progression.
Pembrolizumab with Optional Crossover PeriodBiological
Patient will receive Pembrolizumab monotherapy every 6 weeks until disease progression. Upon verified confirmed disease progression by the blinded independent review central committee, patients may proceed to lifileucel monotherapy during an optional crossover period if they meet eligibility criteria. Optional crossover: A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate and Progression Free SurvivalTime frame: 5 years total duration
Locations
82 sites in 16 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham: The Kirklin Clinic
Birmingham, Alabama · Recruiting
City of Hope
Duarte, California · Recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
California Pacific Medical Center
San Francisco, California · Withdrawn
University of Colorado Cancer Center
Aurora, Colorado · Recruiting
Orlando Health Cancer Institute
Orlando, Florida · Recruiting
University of Illinois Hospital & Health Sciences System
Chicago, Illinois · Withdrawn
University of Kansas
Kansas City, Kansas · Withdrawn
University of Louisville - James Graham Brown Cancer Center
Louisville, Kentucky · Withdrawn
National Cancer Institute
Bethesda, Maryland · Recruiting
Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center
Detroit, Michigan · Withdrawn
Henry Ford Health
Detroit, Michigan · Withdrawn
University of Minnesota
Minneapolis, Minnesota · Recruiting
Dartmouth-Hitchcock Medical Center (DHMC) - Norris Cotton Cancer Center
Lebanon, New Hampshire · Recruiting
MD Anderson Cancer Center at Cooper
Camden, New Jersey · Recruiting
Oncology Hematology Care
Cincinnati, Ohio · Recruiting
Ohio State University
Columbus, Ohio · Recruiting
St. Luke's Cancer Center - Anderson
Easton, Pennsylvania · Withdrawn
Allegheny Health Network
Pittsburgh, Pennsylvania · Recruiting
Baptist Cancer Center
Bartlett, Tennessee · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Intermountain Health
Salt Lake City, Utah · Recruiting
Virginia Commonwealth University
Richmond, Virginia · Withdrawn
Swedish Cancer Institute
Edmonds, Washington · Recruiting
Flinders Medical Centre
Bedford Park, Australia · Recruiting
Westmead Hospital
Westmead, Australia · Recruiting
Greenslopes Private Hospital
Greenslopes, Queensland, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Fiona Stanley Hospital
Murdoch, Western Australia, Australia · Recruiting
Universitair Ziekenhuis Brussel - Oncologisch Centrum
Jette, Belgium · Recruiting
Princess Margaret Cancer Centre
Toronto, Canada · Recruiting
Centre hospitalier de l'Université de Montréal
Montreal, Quebec, Canada · Recruiting
Helsinki University Hospital Comprehensive Cancer Center
Helsinki, Finland, Finland · Recruiting
Institut Paoli Calmettes
Marseille, France · Recruiting
Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu
Nantes, France · Recruiting
Hopital Saint Louis
Paris, France · Recruiting
Universitätsklinikum Carl Gustav Carus
Dresden, Germany · Recruiting
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany · Recruiting
Universitätsklinikum Schleswig-Holstein - Campus Lübeck
Lübeck, Germany · Recruiting
Klinikum Rechts der Isar der Technischen Universität München
Munich, Germany · Recruiting
Showing 40 of 82 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.